Finasteride, pregnancy exposure and male fertility

Most of this site deals in contested evidence. This page does not. The pregnancy section of the label is the most definite writing in the document, and it is the part that gets left out of the summaries most reliably, presumably because it is about somebody other than the person taking the tablet.

Why the warning exists at all

The drug works by stopping testosterone being converted into DHT. DHT is described in the label as a hormone necessary for the normal development of male genitalia. Abnormal male genital development, it says, is an expected consequence when that conversion is inhibited — and it notes that the outcomes resemble those seen in male infants with an inherited deficiency of the same enzyme.

So the risk is not an unexplained finding. It follows directly from the mechanism the drug is built on, which is set out on the pathway page.

What the label instructs

• Use in women who are or may become pregnant is contraindicated — the label places it in Pregnancy Category X.
• The tablet is not indicated for women at all, and not indicated for children.
• Women who are pregnant or may potentially be pregnant should not handle crushed or broken tablets, because of the possibility of absorption.
• Intact tablets are coated, and the label states that the coating prevents contact with the active ingredient during normal handling provided they are not broken or crushed.
• If a pregnant woman does come into contact with a crushed or broken tablet, the label says to wash the contact area immediately with soap and water.

The coating clause is the reason compounded topical products are a separate problem: a cream or spray has no coating, and the FDA's 2025 alert names a greater potential risk of inadvertent exposure to others, specifically women, through transfer of applied product.

What Category X means

The old US pregnancy categories were a five-step scale, and X is the end of it: studies have demonstrated fetal abnormalities, or there is evidence of fetal risk, and the risk clearly outweighs any possible benefit. It is not a caution to be weighed. It is a contraindication.

The animal record the label sets out behind that classification is specific. In pregnant rats given the drug during the period of major organogenesis, hypospadias occurred in male offspring in a dose-dependent way, in 3.6% to 100% of them across the range studied. At much lower exposures, male offspring showed reduced prostate and seminal vesicle weights, delayed preputial separation and transient nipple development. No abnormalities were seen in female offspring at any dose.

Those are animal findings at exposures far above anything a person taking the tablet would produce, and the label is careful about that. They are the reason the contraindication is absolute rather than conditional.

Exposure through semen: what was actually measured

This is the question most people are really asking, and the label contains a specific study rather than a reassurance. Semen levels were measured in 35 men taking the hair-loss tablet daily for six weeks. In 60% of the samples — 21 of the 35 — finasteride was undetectable. Taking the highest level measured in any sample, and assuming complete absorption, the label calculates a daily exposure for a female partner that is 650-fold less than the smallest amount of finasteride shown to have no effect on circulating DHT in men.

There is a second study alongside it, in a species chosen because it predicts human development better than rats. Pregnant rhesus monkeys given intravenous doses reaching roughly 930 times the highest estimated exposure a pregnant woman could receive from the semen of a man on the hair-loss tablet produced no abnormalities in male fetuses. At a vastly higher oral dose — about 120,000 times that estimate — external genital abnormalities did occur, which is what confirmed the model was capable of showing the effect.

Those are the numbers. What the label never does is convert them into permission, and neither will we. If you are trying to conceive, or your partner is or might become pregnant, this belongs in a conversation with a prescriber who can weigh it — not in a calculation done at a kitchen table from a web page.

The man's own fertility

A different question, with a different kind of answer. Male infertility and poor seminal quality appear in the post-approval list — reports rather than trial findings, so no frequency can be attached to them. But the label adds a clause it gives almost nowhere else: normalisation or improvement of seminal quality has been reported after discontinuation of finasteride.

Alongside that, the controlled hair-loss trials recorded a median decrease in ejaculate volume of 0.3 mL, about 11%, against 0.2 mL and about 8% on placebo, after 48 weeks; at five times the hair-loss strength, other studies found a median decrease of roughly 0.5 mL, about 25%, which the label describes as reversible after stopping.

In animal work, decreases in fertility in male rats given hundreds of times the human exposure were reversible within six weeks of stopping, and the label explains why the finding does not translate: it was caused by an effect on accessory sex organs that matters for rat reproduction and not for human.

If a broken tablet has been handled

The label gives one instruction for this and it is not dramatic: wash the contact area immediately with soap and water. It is worth knowing that before it happens, because the moment itself is a bad time to be searching.

Two practical points follow from how the warning is written. The concern is crushed or broken tablets, not intact ones, because the coating is doing the work — so a tablet that has been cut, chipped in a pill organiser or crumbled in a pocket is a different object from one straight out of the pack. And if the question is worrying you at all, a pharmacist can answer it today, for free, without an appointment.

What to take from this

Three things, in order of certainty. The contraindication in pregnancy is absolute and rests on the drug's own mechanism, not on a signal. The measured exposure through semen was small, and 21 of 35 samples had none detectable — with the caveat that this was one study in 35 men. And reports of effects on a man's own semen quality describe improvement after stopping, which is the most hopeful sentence in the whole label.

For everything else the medicine does, start with the main page; for what recovers and what may not, what happens when you stop.